Skip to main content
. 2021 Jan 8;27(5):290–296. doi: 10.5761/atcs.oa.20-00270

Table 1. Characteristic of 85 patients.

Group IPF (n = 17) Non-IPF (n = 68) p Value
Age, median (range) 71 (57–78) 65 (20–80) 0.021
Sex 0.784
 Male, n (%) 11 (65) 39 (57)
 Female, n (%) 6 (35) 29 (43)
Charlson Comorbidity Index 0.828
 0, n (%) 5 (29) 23 (34)
 1, n (%) 7 (41) 29 (43)
 2, n (%) 3 (18) 12 (18)
 >3, n (%) 2 (12) 4 (6)
Smoking 0.506
 Never, n (%) 7 (41) 37 (54)
 Light (B.I. <1000), n (%) 7 (41) 19 (28)
 Heavy (B.I. ≥1000), n (%) 3 (18) 12 (18)
Preoperative serum tests
 KL-6 (U/mL), median (range) 1242 (330–3030) 998 (221–7310) 0.839
 SP-A (ng/mL), median (range) 66.0 (31.6–178.8) 58.8 (14.9–364) 0.924
 SP-D (ng/mL), median (range) 354 (30.6–589) 225 (31.1–1108) 0.129
Preoperative spirometry tests
 FVC (L), median (range) 2.57 (1.33–3.96) 2.68 (1.33–5.47) 0.510
 FVC (% predicted), median (range) 85.0 (52–120) 83.0 (48–129) 0.568
 FEV1 (L), median (range) 2.08 (1.19–3.11) 2.16 (1.10–4.41) 0.746
 FEV1/FVC ratio (%), median (range) 82.7 (62.8–93.2) 78.5 (54.7–95.1) 0.141
 DLCO (mL/min/mmHg), median (range) 12.8 (7.83–16.6) 12.7 (5.45–26.6) 0.470
 %DLCO (% predicted), median (range) 66.0 (44–87) 67.0 (35–154) 0.499

B.I.: Brinkman Index; DLCO: diffuse capacity of the lung for carbon monoxide; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; IPF: idiopathic pulmonary fibrosis; KL-6: Krebs von den Lungen-6; SP-A: surfactant proteins A; SP-D: surfactant proteins D